Awiqli

Scroll down

Introducing Awiqli^® (insulin icodec) — an innovative basal insulin for your type 2 diabetes patients starting on insulin for the first time.

Awiqli<sup>®</sup>’s unique mode of action

Reduces basal insulin injections from 7 to 1 per week¹

Meet Laura 

Patients like Laura can find a way to fit insulin they need into their daily lives.

Reduces basal insulin injections from 7 to 1 per week¹

Meet Laura 

Patients like Laura can find a way to fit insulin they need into their daily lives.

Meet Laura 

Patients like Laura can find a way to fit insulin they need into their daily lives.

Reduces basal insulin injections from 7 to 1 per week¹

Patients like Laura can find a way to fit insulin they need into their daily lives.

Superior HbA_1c reduction and time in range^* vs glargine U100 in insulin-naïve patients with type 2 diabetes²

More insulin-naïve patients with type 2 diabetes reach HbA_1c <7% without hypoglycaemia^†2,3

Reinvent the insulin start experience for your type 2 diabetes patients

^*Target glycaemic range: 70–180 mg/dL.
^†Clinically significant or severe hypoglycaemia in the preceding 12 weeks vs. glargine U100 and degludec.^2,3

Dose Check is a dose guidance app^* designed to make starting and titrating basal insulin simpler for patients with type 2 diabetes.^4,5 It can be offered with Awiqli^® to support your patients on their insulin journey.

^*To support titration of basal insulin and medications that combine basal insulin with GLP-1 RA for type 2 diabetes management.

In the phase 3 clinical trials, ONWARDS 1 and ONWARDS 3, Awiqli® provided superior HbA_1c reduction vs. glargine U100 and degludec in insulin-naïve patients with type 2 diabetes,1–3 suggesting better glycaemic control with the potential advantage of fewer injections.

In ONWARDS 1 and 3, more patients achieved the composite endpoint of HbA_1c <7% without clinically significant or severe hypoglycaemia^* in the preceding 12 weeks with Awiqli^® vs. glargine U100 or degludec.^1–3

Study participants were insulin-naïve patients with type 2 diabetes. Concomitant glucose-lowering agents were permitted from baseline throughout the study periods. In ONWARDS 1, sulphonylureas and glinides were discontinued at randomisation. In ONWARDS 3, sulphonylureas and glinides, if used, were reduced by 50% at randomisation at the investigator’s discretion. A similar proportion of patients, 175 of 984 and 112 of 588 (18% and 19%), were treated with GLP-1 RAs in the glargine U100 and degludec comparisons, respectively.^2,3

 
^*Clinically significant hypoglycaemia is defined as a blood glucose level <54 mg/dL, confirmed with a blood glucose meter. Severe hypoglycaemia is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.^2,3 

^†Clinically significant or severe hypoglycaemia in the preceding 12 weeks in ONWARDS 1: Awiqli^® (n=492) vs. glargine U100 (n=492), and in ONWARDS 3: Awiqli^® (n=294) vs. degludec (n=294).^1,3

The results of the ONWARDS 1 and 3 clinical trials demonstrated less than one clinically significant hypoglycaemic event per patient-year of exposure with Awiqli^®.^1–3

ONWARDS 1: Awiqli^®(n=492) vs. glargine U100 (n=492). End of main phase at 52 weeks: clinically significant or severe hypoglycaemia ERR [95% CI], 1.64 [0.98 to 2.75]. End of trial at 83 weeks: clinically significant or severe - Awiqli^® 0.30/PYE vs. glargine U100 0.16/PYE; ERR [95% CI], 1.63 [1.02 to 2.61].^1,2

ONWARDS 3: Awiqli^® (n=293) vs. degludec (n=294). End of trial (26-week treatment period + 5-week follow-up period) at 31 weeks: clinically significant or severe hypoglycaemia ERR [95% CI], 1.82 [0.87 to 3.80], p=0.11. End of treatment period at 26 weeks: clinically significant or severe hypoglycaemia ERR [95% CI], 3.12 [1.30 to 7.51], p=0.01.^1,3

Scan the QR code above or click on the link below to download your Dosing guidance booklet for Awiqli^® and keep it close by for future reference.

Scan the QR code above or click on the link below to download the summary for future reference.

Awiqli^® can be offered with a dose guidance solution such as Dose Check to support your patients with type 2 diabetes on their insulin journey.

If your patients with type 2 diabetes or type 1 diabetes are already on a conventional daily basal insulin therapy, but you think they may benefit from switching to once-weekly dosing with Awiqli^®, please speak to your local sales representative or visit the booth.

CI, confidence interval; EOR, estimated odds ratio; ERR, estimated rate ratio; GLP-1 RA, glucagon-like peptide-1
receptor agonist; HbA_1c, glycated haemoglobin; PYE, patient-year of exposure.

Awiqli^® (insulin icodec). Summary of Product Characteristics. Novo Nordisk A/S. [June 2024].

Rosenstock J, et al. N Engl J Med 2023; 389:297–308.

Lingvay I, et al. JAMA 2023; 330:228–237.

Patient User Guide - Dose Check.

Dose Check Evidence-Based Titration Plans Reference Document.

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.
The Summary of Product Characteristics (SmPC) is based on the EU SmPC as of May 2024. Registration conditions differ internationally. Always refer to the full local SmPC before prescribing.

HQ24AWQ00153, July 2024

For healthcare professionals only